Skip to main content
Search
search
Link to Facebook page
Link to X
Link to YouTube channel
Link to flipboard
Link to RSS
Main navigation
Home
About
About ACSH
Financials
Our Team
Video
Donate
Publications
Media/Contact
Subscribe
Write For Us
male fertility
email
facebook
twitter
linkedin
pocket
reddit
print
Reversible Male Contraceptive Shows Promise - So Why Stop The Study Early?
As it stands now, the burden of contraception rests heavily on a woman’s shoulders. Male contraceptive options have been limited to the pull-out method, condoms, and the dreaded “V’ word – vasectomy. Understandably, most men shy a
Read more
Can chemicals slow sperm need we worry?
A recent study published in EMBO Repor
Read more
Processed meats under attack again
It s not eno
Read more
Subscribe to male fertility
ACSH relies on donors like you. If you enjoy our work, please contribute.
Make your tax-deductible gift today!
DONATE
Popular articles
Great Women of Science Go Missing: The Matilda Effect
The Pitt's Very Real Depiction of Turmeric Overdose
How Your Body, Not Your Taste Buds, Drives Eating
ACSH Explains: Nicotinamide adenine dinucleotide (NAD)
Kolodny's Kratom Op-Ed is Quite a Piece of Work
ACSH Podcasts
Podcast: Can Everything Kill My Kids? Combating Viral Pseudoscience with Dr. Jess Steier
Podcast: From Boom to Bust and Back: The Real Story of Nuclear Power’s Renaissance
Podcast: Natural = Healthier? Busting Chemophobia Myths with Chemist Dr. Simon Maechling
Podcast: What MAHA Gets Wrong About America's 'Healthy' Past
Podcast: Some People Can't Enjoy Music. Science Has An Explanation
More podcasts
Latest from Josh
Kolodny's Kratom Op-Ed is Quite a Piece of Work
Do Your Amazon Prime Glutathione Supplements Feed Cancer Cells?
The Dopes Make the Poison: EWG’s Annual Dirty Dozen Scare Campaign
Microplastics May Be Overcounted — Here’s Why
More articles
Latest from Chuck
Fructose: An Ancient Signal in a Modern Diet
From Drunken Apes to Defensive Algorithms
In Memoriam: Frederick William Lipfert 1932–2026
Better Tests, Longer Lives, Higher Costs? The ApoB Dilemma
More articles